Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
There is convincing evidence from animal and biomolecular studies that estrogen exerts multiple salutary actions on
the brain, including neurotrophic, neuroprotective, anti-inflammatory, antioxidative and cognition-enhancing effects.
However, results of clinical trials involving hormone therapy (HT) with or without progestins have been controversial. Findings
from the seminal Women�s Health Initiative Memory Study (WHIMS) and others indicated that extended therapy with
conjugated equine estrogen (CEE) and medroxyprogesterone (MPA) increased risk for heart disease, cognitive impairment and
dementia in older postmenopausal women. To date, no single large study has evaluated the potential effects of HT in recently
postmenopausal women in their mid-life. The NIH-funded KEEPS (Kronos Early Estrogen Prevention Study) Cognitive and
Affective Study is the first study that compared the efficacy of two forms of estrogen and characterized the potential effects
of 4 years of therapy with 0.45 mg/day of oral CEE (o-CEE), 50 mcg/day of transdermal estradiol (t-E2) and micronized
progesterone (100 mg twice daily, given cyclically) on cognitive and mood function of 693 recently postmenopausal women
(mean age: 52.7), within 3 years of their last menstrual period. The findings of the study indicated that administration of o-CEE
was associated with significant improvements in mood-related symptoms, as measured by Profile of Mood Scales (POMS),
including depression, anxiety and tension. Cognition as measured by an extensive battery of neuropsychological tests targeting
domains reportedly sensitive to estrogen effects, showed no significant improvements; however, unlike WHIMS and other
studies of HT, no adverse effects were found on any aspect of cognition. Administration of tE2 showed no effects, either on
tests of mood or cognition. Overall, the results of the KEEPS Cognitive/Affective study indicated that therapy with o-CEE for
up to 4 years, exhibits beneficial effects on measures of mood with no adverse effects on cognition. These results favorably alter
the risk-benefit ratio of HT, and suggest that some of the most disabling symptoms of menopause can be effectively managed
by o-CEE therapy in recently postmenopausal women overa limited period.
Biography
Sanjay Asthana is currently Chair in Geriatrics Head, Division of Geriatrics and Gerontology in the Department of Medicine the University of Wisconsin School of
Medicine Madison, WI 53705 USA. He is a Director of NIA/NIH, Wisconsin-Alzheimer�s Disease Research Center (ADRC) in the University of Wisconsin-Madison
School of Medicine and Public Health located at Madison, WI 53705 USA and also he is a Director of Geriatric Research, Education and Clinical Center (GRECC)
In the William S. Middleton Memorial Veterans Hospital located at Madison, WI 53705 USA. He is an Associate Director of Wisconsin Alzheimer�s Institute in the
University of Wisconsin-Madison School of Medicine and Public Health located at Madison, WI 53705 U.S.A. He pursued his graduation in the year 1978 from the
University College of Medical Sciences New Delhi, India. In 1980 in completed his MBBS. 1987 - June 1988 Third year Senior Resident, Department of Medicine
University of Saskatchewan School of Medicine Saskatoon, Canada S7N-OXO. July 1988 - June 1989 he acted as Chief Resident (4th year), Department of
Internal Medicine, University of Saskatchewan, School of Medicine Saskatoon, Canada S7N-OXO.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals